Physician

Michael J Davies, MD

According to 2025 Medicare claims, Michael Davies, MD (NPI: 1588651087) practices allergy/immunology in the Altoona, PA market, with the plurality of this provider's patient population coming from Blair, PA. This provider's primary affiliated billing organization is CENTRAL PENNSYLVANIA ASTHMA AND ALLERGY CARE, LLC (NPI: 1083730857; TIN: 260216930) and primary practice location at 16648-3050.

Davies' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 359 traditional Medicare patients, billed 10,251 HCPCS/CPT codes, and received $237,439 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,776 prescription claims across 461 beneficiaries totaling $1,967,504 in drug costs, led by Takhzyro (Lanadelumab-Flyo). DME data shows 214 claims. Open Payments data shows 11 records totaling $4,750. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $33,742 to $237,439. Similarly, Part D prescription costs have moved sharply higher in recent years, from $313,900 to $1,967,504. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $926 to $3,233.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	236	2,700	$33,742
2016	285	3,072	$43,982
2017	294	4,714	$58,388
2018	379	6,075	$79,889
2019	387	7,211	$90,852
2020	357	13,044	$280,138
2021	389	12,262	$284,100
2022	411	12,213	$262,660
2023	374	13,389	$287,240
2024	359	10,251	$237,439

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	307	1,571	$313,900
2016	324	1,606	$311,701
2017	328	1,580	$431,426
2018	327	1,488	$387,666
2019	336	1,708	$448,881
2020	362	1,827	$383,179
2021	361	1,796	$494,480
2022	391	2,165	$1,154,865
2023	462	2,818	$1,554,453
2024	461	2,776	$1,967,504

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	39	$79,043
2016	N/R	63	$118,239
2017	N/R	100	$155,839
2018	N/R	167	$294,317
2019	N/R	172	$340,217
2020	N/R	124	$222,830
2021	N/R	129	$249,135
2022	N/R	121	$249,616
2023	N/R	135	$301,689
2024	N/R	214	$431,315

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	36	36	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	227	287	$79
94060	Test to measure expiratory airflow and volume changes before and after medication administration	69	88	$25
95165	Professional service for preparation and provision of 1 or more antigens	88	1,925	$10
95117	Professional service for multiple injections of allergen	82	571	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	13	364	$718,427
Xolair	Omalizumab	101	2,828	$282,593
Dupixent Syringe	Dupilumab	48	1,666	$221,762
Nucala	Mepolizumab	39	1,092	$139,836
Dupixent Pen	Dupilumab	33	896	$120,243

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	55	$273,356
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	17	$49,680
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$49,303
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	12	$48,378
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	24	$7,912

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$4,750	CSL Behring
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael J. Davies, MD?

Tedicare shows public-source Medicare data for Michael J. Davies, MD (NPI 1588651087), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael J. Davies, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael J. Davies, MD?

Michael J. Davies, MD is linked to CENTRAL PENNSYLVANIA ASTHMA AND ALLERGY CARE, LLC (billing NPI 1083730857) in the available physician profile data.

Does Michael J. Davies, MD have Open Payments data?

Michael J. Davies, MD has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.